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Abstract: Type 2 diabetes (T2D) is a complex metabolic disease, which involves a maintained
hyperglycemia due to the development of an insulin resistance process. Among multiple risk factors,
host intestinal microbiota has received increasing attention in T2D etiology and progression. In the present
study, we have explored the effect of long-term supplementation with a non-dairy fermented food
product (FFP) in Zucker Diabetic and Fatty (ZDF) rats T2D model. The supplementation with FFP
induced an improvement in glucose homeostasis according to the results obtained from fasting blood
glucose levels, glucose tolerance test, and pancreatic function. Importantly, a significantly reduced
intestinal glucose absorption was found in the FFP-treated rats. Supplemented animals also showed
a greater survival suggesting a better health status as a result of the FFP intake. Some dissimilarities have
been observed in the gut microbiota population between control and FFP-treated rats, and interestingly
a tendency for better cardiometabolic markers values was appreciated in this group. However,
no significant differences were observed in body weight, body composition, or food intake between
groups. These findings suggest that FFP induced gut microbiota modifications in ZDF rats that improved
glucose metabolism and protected from T2D development.
Keywords: diabetes; fermented food; gut microbiota; lactic acid bacteria; postbiotic; probiotic
1. Introduction
Type 2 diabetes (T2D) is characterized by a chronic hyperglycemia preceded by a deranged
insulin sensitivity and/or synthesis. This chronic non-communicable disease accounts for the vast
majority of cases of diabetes, more than 90% [1], being one of the most prevalent illnesses. Importantly,
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T2D is associated with over 70% of global deaths [2]. Genetic factors contribution is unlikely to be
responsible for the increasing T2D incidence because of the genome stability, although physicians and
the scientific community have also focused on environmental factors [3,4]. One possible explanation
hypothesizes the role of microorganisms that coexist with us [5]. The gut microbiota (GM) is the bigger
reservoir (1014 microbes) [5] and is considered an organ because of its crucial metabolic and defense
competences [6]. Its anomalous distribution or activity, named dysbiosis [7], has been related to a wide
group of illnesses and physiopathological conditions [8]. Specifically, there is evidence that diabetes
occurs in association with a compromised gut environment and a large body of research highlights
a plausible connection between T2D and GM [9–11]. For instance, a compromised abundance
of beneficial bacteria [12] or increase of infrequent species [13] have been reported in T2D and
obese individuals.
The GM displays some plasticity and different strategies resulted in marked changes.
Among the studied approaches, dietary modulation was successful in causing significant changes
in the GM [13,14]. Probiotics, prebiotics, symbiotics, and fermented foods are known to confer
health benefits on the host by improving GM performance and have been proposed as novel clinical
strategies for T2D [6,15,16]. For instance, probiotic supplementation with Lactobacillus G15 and
Q14 showed improved glucose tolerance in streptozotocin (STZ)-induced type 2 diabetic rats [17].
Human intervention studies have also shown good results. A crossover trial with prediabetic
individuals reported a reduced insulin resistance after kimchi consumption [18], and a randomized
controlled trial in T2D subjects supplemented with a fermented milk with the probiotic Lactobacillus casei
strain Shirota showed a healthier gut ecosystem with strengthened gut barrier function along with
modulation of microbial communities [19].
The most widespread fermented products are dairy products like yogurt, kefir, or dahi.
Nonetheless, other food matrixes like fruits, vegetables, or cereals have also been studied and
showed many beneficial effects on health [20]. Indeed, some attractive advantages over dairy products
have been described for them [21]. In the present study we have tested the effectiveness of a
non-dairy fermented food product (FFP) in preventing the T2D and obese phenotype developed
by the Zucker diabetic fatty (ZDF) rat model. This murine model presents a mutation in the leptin
receptor accompanied with an enhanced β-cell destruction and impaired glucose homeostasis, and is
a widely used model for T2D studies [22,23]. Previous research reported the effectiveness of probiotics
in the attenuation of the diabetic and obese phenotype in ZDF rat model [24] and other rodent
models [25,26]. However, few researchers have tested the efficiency of fermented food on the diabetic
phenotype and previous works have only focused on dairy products [27]. On top of this, the literature
on probiotic microorganisms indicates that the functional attributes of the cells are to a large degree
dependent on the strain [28,29]. Therefore, an individual characterization should be performed for each
study product. Our fermented food product derives from a fermented feed, which has previously
demonstrated the ability to improve health and wellness in farm animals (HEALTHSTOCK Ref.
733627; https://cordis.europa.eu/project/rcn/206082/factsheet/es). Consequently, FFP has been used in a
controlled in vivo study (ZDF rat model) in order to demonstrate its benefit in glycemic control and
in comorbidities derived from hyperglycemia.
2. Materials and Methods
2.1. Product Description
The fermented food product tested is a plant-based food product primarily composed by soya
flour, alfalfa meal, and barley sprouts along with other minor components (including skimmed milk
powder). The FFP is defined as a non-probiotic product classified as fermented food [29]. During the
production process a combination of specific LABs and non-bitter beer yeast is incorporated to the raw
materials and a classical fermentation process is performed. The FFP has been produced using standard
culture medium Tryptic Soya Agar (TSA) in microaerophilic conditions at 37 ◦C until microorganisms’
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concentration achieve at least 109 microorganisms/mL in an exponential growth phase or close
to the stationary phase. The manufacturing as well as the pool of microorganisms intentionally added
are responsible for the viable microorganisms and composition of the final product (Tables S1 and S2).
The FFP is presented as a dry granulated product, with an average particle size ranging from 4 to 12 mm
(Figure S1) with a moisture content of 12.8% and a pH of 4.4. The metagenomics analysis revealed that
Firmicutes is the most predominant phylum (38.7%), followed by Proteobacteria (26.7%), Bacteroidetes
(18.3%), Actinobacteria (14.5%), and lately TM7 (1.8%). At genus level, Lactobacillus are the most
predominant accounting for more than 6% of identified species.
2.2. Animals and Experimental Design
Eleven weeks-old male ZDF rats (n = 16) (Charles River Laboratories) were acclimated for five
weeks and housed in a controlled environment (a room with constant temperature and humidity
under a 12:12 h light-dark cycle) with ad libitum access to food (standard rodent chow) and water.
Animals were randomly divided and allocated into two groups: A control group (C group) (n = 8) and
a group supplemented with FFP (T group) (n = 8). ZDF rats were housed at four animals per cage.
After the acclimatization period, all animals were given hypercaloric diet (HD) (TD.06416; Envigo)
until the end of the study, which lasted 31 weeks (see composition of HD in Table S2). The T group was
additionally fed with FFP (200 g per cage and week). See the experimental design scheme (Figure S2).
The glucose uptake assay, the insulin positive cell quantification such as the analysis of the microbiota
were analyzed by blinded investigators.
Animal procedures were performed in accordance with the “Principles of Laboratory Animal
Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use
of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources, Commission on
Life Science, National Research Council, and published by the National Academy Press, revised 1996.
All animal procedures were approved by the Institutional Committee on Care and Use of Laboratory
Animals (CEEA, University of Navarra) (Protocol number: CEEA/117-15).
2.3. Fasting Blood Glucose and Intraperitoneal Glucose Tolerance Test
Animals were fasted 24 h and blood samples were collected from the tip of the tail vein in order
to determine blood glucose levels by using a glucometer (Accu-chek Aviva, Roche, Basel, Switzerland).
Fasting blood glucose (FBG) was recorded once a week.
For glucose tolerance test (GTT) determination, 24 h fasted animals received glucose
(Baxter, Valencia) intraperitoneally (1.5 g/kg of body weight) and glycemia was determined as described
for FBG at different time points (baseline, 20, 40, 60, 90, 120, and 150 min) after glucose injection.
GTT was conducted at one and two months after the start of the study. The area under the curve (AUC)
of glucose values was assessed for each group from 0 to 150 min post glucose injection.
2.4. Body Weight, Food Intake and Body Composition
Body weight (BW) was measured once a week with an electronic balance. HD food intake was
monitored weekly for 12 weeks. The weekly HD intake mean was estimated for the two experimental
groups as grams per week and animal. Also, body composition was determined for each group
(n = 4 in C group; n = 5 in T group) using nuclear magnetic resonance (EchoMRI, EchoMedical Systems,
Houston, TX, USA) at the end of the study.
2.5. Analysis of Functional Properties: C-peptide Synthesis and Intestinal Glucose Uptake Assays
Blood C-peptide concentration (ng mL−1) was quantified with a commercial C-Peptide ELISA kit
(Crystal Chem Europe) at time points four and seven months from the beginning of the study. HOMA-IR
and HOMA-β were determined at the end of the study. HOMA-IR was calculated by the formula:
HOMA-IR = serum C-peptide (ng mL−1)*blood glucose (mmol L−1)/22.5; and HOMA-β was calculated
by the formula: HOMA-β = 20*serum C-peptide (ng mL−1)/(blood glucose (mmol L−1) − 0.35).
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The effects of in vivo FFP supplementation on the uptake of α-Methyl-D-glucoside (α-MG),
a SGLT-1 specific substrate, were determined on everted jejunal rings obtained from the animals
as previously described [30]. Briefly, at the end of the study, animals were sacrificed, the jejunum
obtained, and groups of six rings were incubated at 37 ◦C for 15 min under continuous shaking
in Krebs-Ringer-Tris (KRT) solution gassed with O2. The solution contained 1 mM α-MG and
0.0025 µCi mL−1 of [14C] α-MG (Ge Healthcare, Little Chalfont, UK). At the end of the incubation
period, rings were removed from the medium, weighed, and the accumulated substrate was extracted
from the rings for 15 h in 0.1 M HNO3 at 4 ◦C. Finally, duplicate aliquot samples were taken for liquid
scintillation counting. α-MG uptake was estimated from the relationship between the counts per
minute recorded for the incubation medium and the counts per minute obtained for the HNO3 aliquots
and expressed as micromoles of α-MG per gram of wet weight (w.w.) per 15 min.
2.6. Lipid Profile and Hepatotoxicity Markers
In order to determine the lipid profile, fasting blood samples were extracted from the dorsal pedal
vein under anesthesia (5% isoflurane in oxygen) at baseline, two, four, and seven months of the study.
Samples were centrifuged 15 min at 13,000 rpm and stored at −80 ◦C for biochemical analysis. Also,
serum total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C),
triglycerides (TG) and aspartate and alanine amino-transferases (AST and ALT, respectively) were
analyzed (Cobas c311 analyzer, Roche, Basel, Switzerland). The atherogenic index (AI) was estimated
using the formula log(TG/HDL-C) as previously described [31].
2.7. Tissue Collection and Histological Analysis
After 31 weeks of study, o/n fasting animals were sacrificed by decapitation. The pancreas and
fat tissues (retroperitoneal, epidydimal, mesenteric, subcutaneous, and brown fat) were immediately
removed, weighted, and fixed in 10% buffered formalin.
Fixed pancreas samples were embedded in paraffin blocks, cut at a thickness of 3 µm and
analyzed by immunohistochemistry (n = 4 for each group). Immunolabelling was performed with
an antibody against insulin (dilution 1:8000, A0564 Dako) and a secondary antibody labeled with
HRP (dilution 1:100, P0141 Dako). All sections were observed under an optical microscope using the
10× objective lens (Olympus CH, Shinjuku, Japan) and insulin positive cells were counted. Nine serial
sections were analyzed for each pancreas.
The total area (mm2) of the analyzed sections was calculated. For this purpose, slides containing
the stained histological samples were digitized (APERIO CS2, Leica Biosystems, San Diego, CA, USA)
and images were analyzed using the ImageJ 1.52 software. The results of the quantification are shown
as insulin-positive cells per pancreas area (insulin positive cells/mm2) at the end of the study.
2.8. Faecal Microbiota Analysis
Rat feces were collected at six months of study and immediately frozen at −80 ◦C for the purpose
of metagenomic analysis. 16S rRNA sequences obtained were filtered following quality criteria
of the OTU processing pipeline LotuS (release 1.58) [32]. This pipeline includes UPARSE de novo
sequence clustering [33], removal of chimeric sequences and phix contaminants for the identification
of operational taxonomic units (OTUs), and OTU abundance matrix generation. Finally, taxonomy was
assigned using BLAST [34] and HITdb [35] achieving up to species-level sensitivity. The abundance
matrices were first filtered and then normalized in R/Bioconductor [36] at each classification level:
OTU, species, genus, family, order, class, and phylum. Briefly, taxa were discarded for future analysis
when less than four reads were obtained in more than 50% of the samples of both experimental
conditions, and a global normalization was performed using the library size as a correcting factor and
log2 data transformation. Linear models for microarray data (LIMMA) [37] was used to identify taxa
with significant differential abundance between experimental conditions. The selection criteria was
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based on an FDR cut-off (FDR < 0.05). Further clustering analyses and graphical representations were
performed using R/Bioconductor [36].
2.9. Statistical Analysis
Statistical analysis was performed with the SPSS 22.0 for windows software package. Normality
and variances homogeneity were tested with the Shapiro–Wilk and Levene tests, respectively. For values
showing normal distribution, comparisons were carried out using unpaired and paired Student’s
T-test and in case of non-normal distribution, U-Mann-Whitney test. Results are expressed as
mean ± standard deviation (SD). Statistical significance was set at p < 0.05 and p < 0.01 was considered
as highly significant.
3. Results
3.1. FFP Supplementation Leads to Lower Fasting Blood Glucose Levels and Improves Glucose Tolerance
In order to determine the effectiveness of FFP supplementation to control blood glucose levels
in ZDF rats supplemented with HD we have performed a FBG determination on ZDF rats fasted during
24 h. No significant differences between groups were observed in FBG values basally (Figure 1A).
However, after four weeks of supplementation, animals in the T group exhibited lower FBG values
than animals in the C group (8.0 ± 1.8 versus 12.0 ± 2.7 mmol L−1, respectively; p = 0.004). Statistical
significant differences between groups were also found in week six (p = 0.038), week 14 (p = 0.013),
week 16 (p = 0.013), week 21 (p = 0.005), week 22 (p = 0.026), week 24 (p = 0.001), week 27 (p = 0.03),
week 28 (p = 0.001), and week 31 (p = 0.016) as represented in Figure 1A. Initial and final FBG values
were compared in the C group showing no statistical significant differences, despite the observed
differences were very high (p = 0.125); on the other hand, initial and final FBG values in the T group
are comparable and no statistically significant differences were found (p = 0.625) (Figure 1B). Although,
one-month period was not enough to display significant differences in GTT between groups (data not
shown), after two months of supplementation, the T group showed lower glycemic values versus
the C group although not all the time points showed significance (Figure 1C). Statistically significant
differences were found at GTT time point 20 min (p = 0.034), 40 min (p = 0.007) and 120 min (p = 0.038)
time points of the GTT. Glucose AUC showed higher values in the C group with a p value in the limit
of significance (p = 0.05) (Figure 1D). These findings suggest that rats supplemented with the FFP
exhibited a better glucose metabolism control than those fed exclusively with HD (C group).




Figure 1. Effect of the fermented food product (FFP) on glucose metabolism. (A) Weekly fasting blood 
glucose (FBG) progression in Zucker diabetic fatty (ZDF) rats. Animals in T group showed lower FBG 
mean values than animals in C group during the study. Statistically significant differences were found 
at 4, 6, 14, 16, 21, 22, 24, 27, 28, and 31 weeks (p = 0.004, p = 0.038, p = 0.013, p = 0.013, p = 0.005, p = 
0.026, p = 0.001, p = 0.030, p = 0.001, and p = 0.016, respectively). (B) Bar plots represent basal and end 
point FBG values in the groups. No statistical significant differences were found between basal and 
end point FBG values in any groups (7.2 ± 1.3 versus 19.5 ± 6.3 mmol L−1 at 0 and 31 weeks, respectively 
in C group; 7.6 ± 1.8 versus 8.2 ± 1.6 mmol L−1 at 0 and 31 weeks respectively in T group). (C) Two-
months glucose tolerance test (GTT) curve. The GTT curve, after two months of FFP supplementation, 
showed lower blood glucose levels and statistically significant differences between groups were 
found at 20, 40, and 120 min (p = 0.034, p = 0.007, and p = 0.038, respectively). (D) Area under the curve 
(AUC) plot. The AUC value was lower in T group (3622.5 ± 1040.4) compared to C group (4454.0 ± 
590.9) although the p value obtained was in the limit of significance (p = 0.05). Values are expressed 
as mean ± SD. wk = week. * p < 0.05, ** p < 0.01. 
Figure 1. Cont.
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Figure 1. Effect of the fermented food product (FFP) on glucose metabolism. (A) Weekly fasting
blood glucose (FBG) progression in Zucker diabetic fatty (ZDF) rats. Animals in T group showed
lower FBG mean values than animals in C group during the study. Statistically significant differences
were found at 4, 6, 14, 16, 21, 22, 24, 27, 28, and 31 weeks (p = 0.004, p = 0.038, p = 0.013, p = 0.013,
p = 0.005, p = 0.026, p = 0.001, p = 0.030, p = 0.001, and p = 0.016, respectively). (B) Bar plots represent
basal and end point FBG values in the groups. No statistical significant differences were found
between basal and end point FBG values in any groups (7.2 ± 1.3 versus 19.5 ± 6.3 mmol L−1 at 0 and
31 weeks, respectively in C group; 7.6 ± 1.8 versus 8.2 ± 1.6 mmol L−1 at 0 and 31 weeks respectively
in T group). (C) Two-months glucose tolerance test (GTT) curve. The GTT curve, after two months
of FFP supplementation, showed lower blood glucose levels and statistically significant differences
between groups were found at 20, 40, and 120 min (p = 0.034, p = 0.007, and p = 0.038, respectively).
(D) Area under the curve (AUC) plot. The AUC value was lower in T group (3622.5 ± 1040.4) compared
to C group (4454.0 ± 590.9) although the p value obtained was in the limit of significance (p = 0.05).
Values are expressed as mean ± SD. wk = week. * p < 0.05, ** p < 0.01.
3.2. Body Weight, Body Composition, a d Food I take after FFP Consumption
Initial body weight values were similar between groups (p = 0.610) and BW increase was steady
and similar within the groups during the first eight weeks of study, time at which different trends
were observed between groups. From week eight onward, the T group continued gaining weight
whereas the C group did not increase BW and even a weight loss was observed at the end of the study
(Figure 2A).
Regarding the BW gain (difference between end point and basal BW values), statistically significant
differences were observed in the T group (p = 0.031), while the C group did not experiment statistical
significant changes over time (p = 0.625) (Figure 2B).
No statistically significant differences were found in HD food consumption between both groups
(p = 0.413) (Figure 2C). Interestingly, data on food intake differs from the outcomes found in BW,
which indicates that animals supplemented with the FFP showed a greater BW gain.
Body composition was evaluated before sacrifice and despite the asymmetry of BW found
at the end of the study, no statistically significant differences within groups were assessed in fat mass
percentage (p = 0.630). Both groups also exhibited similar mean values of lean mass (p = 0.641) and
other tissues relative percentage (p = 0.947) (Figure S3). These results suggest that the supplementation
with the FFP did not alter body composition in ZDF rats fed with HD. Supporting the previous
presumption, the weights of retroperitoneal, epidydimal, mesenteric, subcutaneous, and brown fat
mass collected at sacrifice did not statistically differ between experimental groups (Table S3).
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(A) between the experimental groups in spite of heir divergent growing tendencies. BW gain (B) was
statistically significant in T group (346.0 ± 18.4 versus 533.5 ± 165.8 g at baseline and at the end point,
respectively; p = 0.031) but no statistical significant differences were found in C group (352.3 ± 9.9 versus
416.8 ± 60.3 g at baseline and at the end point, respectively; p = 0.625). The FFP administration did not
alter HD food intake (C), which was comparable in bo h groups (101.9 ± 16. versus 96.5 ± 15.7 g in C
an T groups, espectively; p = 0.413). Values are expressed as mean ± SD. * p < 0.05.
3.3. FFP Preserves Normal Metabolic and Biochemical Parameters
Comparisons of lipid profile and hepat toxicity markers between and within groups are available
in Table S4. No statistically significant differences were found at baseline in any of the explored
parameters between both experimental groups, except for LDL-C (p = 0.021) and TG mean values
(p = 0.025). During the study both groups experimented an increase in LDL-C values and the magnitude
was greater in the C group than in the T group (p = 0.001 and p = 0.023, respectively). Although baseline
TG levels were significantly lower in the C group (p = 0.025), a statistically significant increase
was observed for the same group after seven months of study (p = 0.043) while T group remained
unchanged. Indeed, significant differences were appreciated between groups at the end of the trial
(p = 0.01). Somehow the FFP could restore and normalize TG values. Regarding TC, both C and
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T groups showed the same tendency of increase at the end of the study (p = 0.00 and p = 0.011,
respectively) and the same response was found in LDL-C (p = 0.01 and p = 0.023 in the C group and T
group, respectively). Taken together, pairwise comparisons between all of the follow-up time points
revealed that at the end of the study both groups showed significantly greater serum levels of TC,
LDL-C, and HDL.
With respect to the liver function and the stress induced by the HD, serum AST and ALT levels
were determined along the intervention as well. For both parameters, statistically significant differences
were found between T and C groups at two months of study, when a peak on serum AST and ALT
was observed: The T group showed significant lower values of both AST and ALT (p = 0.001 and
p = 0.019, respectively). After the aforementioned peak, transaminase levels were normalized, and such
reduction was more pronounced in the group supplemented with FFP (Figure 3A). The AI showed
statistically significant differences between groups at baseline (p = 0.023) and at the end of the study
(p = 0.020) (Figure 3B). The T group presented a tendency with a better health status in the T group
and when pairwise comparison was made, the treated group exhibited an improved and reduced AI at
the end of the study in contrast with its baseline value (p = 0.027). Regardless the tendency observed
in Figure 3B the C group did not present marked differences on AI over time.
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Figure 3. Transaminases level, atherogenic index and survival rate in ZDF rats. (A) Transaminase
levels. Statistical significant differences were observed in aspartate and alanine amino-transferases
(AST and ALT) at two months of study, being that the C group clearly shown higher concentrations
of both AST (632.1 ± 208.9 versus 238.9 ± 112.6 UI L−1 in C and T groups, respectively; p = 0.001) and
ALT (348.0 ± 192.2 versus 90.0 ± 54.6 UI L−1 in C and T groups, respectively; p = 0.019). (B) Atherogenic
index. Statistically significant differences were observed in basal (1.9 ± 0.1 versus 2.1 ± 0.1 in C and
T groups, respectively; p = 0.004) and end point values of atherogenic index (AI) (2.1 ± 0.2 versus
1.8 ± 0.1 in C and T groups, respectively; p = 0.015). (C) Kaplan-Meier plot. The T group demonstrated
a greater survival rate (87.5%) compared to the C group (50%). The survival time was higher in the T
group (27.6 ± 5.6 versus 30.6 ± 1.1 weeks in C and T groups, respectively, p = 0.106) but no significant
differences between both groups were found. Data are represented as mean ± SD. * p < 0.05; ** p < 0.01.
Overall, the group supplemented with FFP displayed a healthier phenotype, what is also
supported by data on survival rate (Figure 3C). Animals in the T group exhibited a tendency of longer
life expectancy (30.6 ± 1.1 weeks) compared to the animals included in the C group (27.6 ± 5.6 weeks)
(p = 0.106). Throughout the experimental study, five rats died. The deceased animals presented clear
T2D symptoms including a maintained hyperglycemia, marked weight loss, greater water consumption
(polydipsia), and wetter cage floor due to increased urine excretion (polyuria) [1,38,39] according
to the ZDF animal model disease progression [23]. Four of them belonged to the C group (these rats
died at week 15, week 26, week 26, and week 30 of study) and only one to the T group (the rat died at
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week 28 of study). Those results indicate that the supplementation with FFP increase the survival rate
at the end of the study (87.5% in the T group) in contrast to the C group (50%).
3.4. The Administration of FFP Allows the Maintenance of Normal Pancreatic Activity
Blood insulin levels, measured as C-peptide cleavage secretion, were determined at two different
time points (four months and seven months) in both groups. The results indicate that although
a tendency to protection in the secretion of insulin was observed in the group treated with FFP,
no significant differences were found between T group and C group at four and seven months
(p = 0.234 and p = 0.792, respectively) (Figure 4A). Besides, when looking to the ability to synthetize
insulin, no significant differences were detected in the total area of insulin-positive cells of pancreatic
tissue in both experimental groups (p = 0.114). With the aim of evaluating β-cells efficiency in insulin
synthesis, we assessed the correspondence between the quantified positiveβ-cell number and C-peptide
levels in serum at the end of the study. The results suggest a higher value of C-peptide levels/β-cell
in the T group although no significant differences were found (p = 0.114) (Figure 4B).
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Figure 4. Pancreatic function. (A) No statistical significant differences were found between serum
C-peptide levels in C and T groups at four months (6.2 ± 1.7 versus 9.1 ± 6.6 ng mL−1, respectively;
p = 0.234) and seven months (7.6 ± 1.7 versus 8.5 ± 4.6 ng mL−1, respectively; p = 0.792). (B) When values
of C-peptide/insulin positive cells were determined, a higher value was found in T group although
statistical differences were not found (0.2 ± 0.1 versus 0.3 ± 0.1 ng mL−1 mm−2 in C and T groups,
respectively, p = 0.114). The homeostatic model assessment (HOMA)-IR (C) did not reflect differences
among groups, however statistical significant differences were found in HOMA-β (D), between T and C
groups (26.6 ± 18.2 versus 9.0 ± 2.9, respectively; p = 0.029); (n = 4 in C group and n = 4 in T group).
Results are expressed as mean ± SD. * p < 0.05.
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With respect to the homeostatic model assessment (HOMA) no significant differences were
observed in the HOMA-IR (p = 0.114). However, statistical significant differences were found
in the HOMA-β (p = 0.029), remarking a better β-cell functionality in the group supplemented with
the FFP (Figure 4C,D).
3.5. FFP Supplementation Induces a Decrease in Intestinal Glucose Uptake
To test whether the hypoglycemic actions of FFP supplementation could be related to a decrease
in intestinal sugar uptake, we measured the ex vivo α-MG uptake in intestinal everted rings from
animals after treatment. A significant decrease in intestinal α-MG uptake was observed in animals
receiving FFP compared to the control group (p = 0.029) (Figure 5).
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Figure 5. Intestinal glucose uptake. When intestinal glucose transport was determined, it was found that
animals administered the FFP (T group) exhibited statistically sig ificant lower marked glucose uptake
compared to ani als in C group (1.7 ± 0.7 versus 2.9 ± 0.6 micromol MG g wet weight−1 15 min−1;
p = 0.029); (n = 4 in C group and n = 5 in T group). Results are expressed as mean ± SD. * p < 0.05.
3.6. The Administration of the FFP Altered the Composition of Faecal Microbiota
At phylum level, Firmicutes, Proteobacteria, Bacteroidetes, and Actinobacteria were the more
predominant phyl present in the fecal samples of both gr ups (Figure 6A). After FFP supplementation,
the percentage of Firmicutes was statistical significantly higher in the C group than in the T group
(p = 0.017) and no statistical differences were found between groups in the Bacteroidetes phylum
(Figure 6B), probably due to the variability observed. The ratio of Firmicutes to Bacteroidetes is a widely
used indicator of the microbial composition, however in our study its value was comparable in both
groups (1.23 versus 1.08 in C group and T group, respectively). At the family level the more abundant
taxa were Lactobacillaceae (4.1%), Enterobacteriaceae (3.6%), Porphyromonadaceae (3.6%), Lachnospiraceae
(3.5%), and Ruminococcaceae (3.4%) (Figure S4). Statistically significant differences were only observed
in Streptococcaceae (p = 0.046) and Sutterellaceae (p = 0.046) families. The Streptococcaceae family was
higher in C group while the Sutterellaceae was higher in T group (Figure 6C).
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Figure 6. Fecal microbiota composition at phylum, family and genus level. (A) Relative abundance
of phyla present in fecal samples in C and T groups. (B) Contributions of Firmicutes and Bacteroidetes.
The abundance of Firmicutes was statistically significant higher in the C group than in the T group
(p = 0.017) however no statistically significant differences were found in Firmicutes to Bacteroidetes ratio;
(n = 3 in C group and n = 3 in T group). (C) Fecal microbiota composition at family level. Streptococcaceae
contribution was significantly higher in the control rats than in the treated ones while Sutterellaceae
was enriched in the treated animals; (n = 3 in C group and n = 3 in T group). (D) Widespread effect
of the administration of the FFP on bacterial genera. Representation of statistically significant genera
between groups at six months. Sutterella and Proteus were found enriched in the T group whereas
Anaerococcus and Streptococcus were more prominent in the C group; (n = 3 in C group and n = 3 in
T group). * p < 0.05, *** p < 0.01.
The study of the total abundance of the genera revealed that the dominant bacteria genera were
Lactobacillus (2.85%), Clostridium (2.26%), Bifidobacterium (2.26%), Barnesiella (2.22%), and Bacteroides
(2.17%). From all 123 different identified genera, four and 19 were found exclusively in C or T
groups, respectively (Tables S5 and S6). At genus level, the supplementation with the FFP enriched
the abundance of Sutterella and Proteus, which were found more prominent in the T group (p < 0.001
and p = 0.032, respectively), while Anaerococcus and Streptococcus were more copious in control animals
(p = 0.032 for both genera) (Figure 6D).
Nutrients 2019, 11, 2530 12 of 23
A sum of 433 different bacterial species were identified in all the samples, of which 26 and 100 were
exclusive of the C and T group, respectively (Tables S5 and S6). A mutual core of 307 shared species
was found in the two groups and among them 30 bacterial species significantly differed in the number
of total sequences (Figure 7).
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Figure 7. Hierarchical clustering. Hierarchical clustering of differentially abundant species (p < 0.05)
in C group and T group at six months; (n = 3 in C group and n = 3 in T group).
Diversity of the fecal microbiota were also analyzed. Alpha diversity indexes of bacterial
community in ZDF rats are presented in Table 1. The alpha diversity was greater in T group than in C
group, as samples in control group are perceived to have lower value in four of the five analyzed indexes.
This may suggest that the administration of the FFP lead to an enrichment of the microbial diversity.
Table 1. Ecological indexes of Alpha diversity.
Sample ACE Chao1 Observed Species Shannon Simpson
C group 2235.43 ± 314.85 2280.57 ± 322.74 1900.00 ± 298.08 4.99 ± 0.72 0.98 ± 0.01
T group 2837.85 ± 668.01 2868.51 ± 646.40 2510.67 ± 655.89 5.04 ± 0.76 0.98 ± 0.02
Values expressed as mean ± SD.
A non-metric multidimensional scaling analysis (NMDS) was performed in order to analyze
the observed variability. The NMDS plot (Figure 8) showed that the distances between samples from
the C group are shorter than those between samples in the T group. This means that C group presents
a higher microbial homogeneity and so animals were more similar to each other than the treated animals.
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4. Discussion
Recent findings regarding T2D have led to new valuable knowledge on diabetic etiology and
risk factors. Specifically, considerable interest exists in the role of the GM in the development and
progression of diabetes. Several publications showed that diabetic individuals present a characteristic
intestinal microbial community. This distinctive GM includes altered abundance of some bacteria
taxa, for instance increased presence of Lactobacillus genera and opportunistic pathogens, along with
differences in metabolic functionality, such as enhanced sulphate reduction and oxidative stress
resistance [12]. Moreover, there is evidence that the GM influences the progression of the diabetes
and its related complications [40] and its restoration resulted in clinical improvements according
to experimental and clinical data. In particular, diet appears to play a key role and nutritional
interventions have received attention for their ability to normalize the intestinal microbiota and thus
improve health status [41].
In the present study a non-dairy fermented product was tested for its effectiveness in relieving
the diabetic phenotype in the ZDF model. Among our experimental data, the markedly decreased
glucose absorption in the treated group is probably the most striking result to emerge. Although extreme
caution must be taken when extrapolating the results from ex vivo experiments, our result suggests
that the total glucose which reach the systemic circulation was strongly attenuated with the FFP
supplementation. This would support the lower BFG and GTT values observed in the T group.
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We hypothesized that the FFP is able to improve the intestinal integrity and to decrease the load of glucose
which reach the systemic environment, as suggested by previous authors [42]. A body of evidence has
indicated an altered gut environment in diabetic people which includes a compromised tight-junction
structure [43], a disrupted gut barrier [40], and impaired glucose transporters in the gut [42]. Taking it
all into consideration, any approach that pursue to restore the gut health would eventually induce
beneficial changes in the host.
A slightly higher value of C-peptide was also noticed in the supplemented group. The concentration
of C-peptide represents an indirect estimation of β-cell activity as it leaks from proinsulin cleavage [44].
On the other hand, although the number of insulin positive cells present in the pancreas of the C group
was greater, we observed that β-cells were more efficient in the T group because a higher endogenous
insulin production per β-cell was measured. Such findings indicate that the β-cell mass was best
preserved in the T group. This is in good agreement with the HOMA-β score, and all together suggests
a healthier pancreatic function in the T group. We believe that the treatment indirectly protected from
organs dysfunction through a systemic effect, which together with the normalized values of glycemia
observed in the T group in both BFG and GTT determinations could be responsible for the better
pancreatic activity reported in this group.
Both the restoration of the glucose homeostasis and the protection of the pancreatic activity could
be responsible for the improved wellness of the treated ZDF rats. A correct glucose metabolism can
lessen alterations in cardio-metabolic parameters and result in a healthier lipid profile. Based on
the physiological process of the T2D, also mimicked in the ZDF rat model, a deterioration in the lipid
profile would be predicted along with the diabetes progression in both groups. However, our data
reflected better values of TG, transaminases, and AI index in the T group. In this context, the observed
results may suggest that the FFP helped to some extent to prevent diabetes-associated secondary
alterations. Most of the analyzed parameters in the current research showed a tendency of a healthier
status in the T group, and this trend was strongly manifested along the study by the greater survival
observed in the supplemented group. As a result, the FFP-treated animals showed a prolonged
survival in comparison with the control animals. It is also worth noting that the only animal that died
in the group treated with FFP did so in week 28, while the first animal that did it in the control group
was in week 15.
In addition to the mechanisms outlined above, another feasible explanation for the better glucose
homeostasis in the T group is that the GM functional properties were affected by the FFP, and the ability
to metabolize glucose was increased in some bacteria groups. Gut dysbiosis has been described
in relation to glucose dyshomeostasis and emerging experimental and clinical evidence suggests
that GM activity is modified in T2D [12,40,45,46]. Because of the key endocrine function exerted by
the GM [47], restoring its metabolic function is a valuable approach which proved to be successful
in provoking significative changes [14]. In the metagenomic analysis of the fecal microbiome obtained
from the ZDF rats performed in the present study we could identify some differences among groups’
samples and some results did not confirm previous research on the topic. For instance, we did not find
significant differences in Firmicutes to Bacteroidetes ratio. It is a relevant but controversial microbial
marker. A reduced Bacteroidetes contribution or increased Firmicutes to Bacteroidetes ratio have
been reported in obesity [48], and this parameter was found to be partially restored following weight
loss [49] or prebiotic treatment [50]. On the contrary, other researchers have reported a significantly
higher Firmicutes to Bacteroidetes ratio in lean than in overweighed or obese individuals [51]. In line
with this observation, our results indicate a significant higher contribution of Firmicutes in the T group;
however, our data did not reveal significant differences in the aforementioned ratio. Unlike other
investigations carried out on the topic, we did not find a significant increase in Bifidobacterium levels.
Based on the characteristics of the FFP, whose composition includes a high level of fermentable
carbohydrates [52], a bifidogenic effect was expected in the T group due to the metabolites obtained
during the fermentation process of FFP. This change is desired because this bacteria genera is a health
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marker [53]. However, our results indicate that the analyzed product or the experimental design could
not induce a bifidogenic effect.
At the family level, Streptococcaceae was found significantly enriched in the control group,
which matches with a previous type 1 diabetes (T1D) human trial [54]. On the contrary, Sutterellaceae
family, which includes commensal species found in healthy human and animals [55], was more
predominant in the treated group. At the genus level a significant enrichment was observed in Sutterella
in the treated group. This finding does not corroborate previous results from earlier case-control
studies in prediabetic subjects [56], experimental studies on type 1 diabetic animal models [57] and
reports in other pathological conditions such as autism [58] and atopic dermatitis [59]. However,
our finding matches to a previous investigation that associated barley consumption, a main component
in FFP formulation, with an elevated abundance of Sutterella in the human GM [60]. Proteus genus
was also enriched in the supplemented rats. Although there is no evidence about the function of this
genus in diabetes or obesity, some authors suggest its role in some pathological conditions [61,62].
In fact, one specie, P. mirabilis, was negatively correlated to health improvements [63,64], what suggests
that a low abundance should be wanted. In contrast, our metagenomic analysis revealed that
P. mirabilis was significantly enriched in the treated group. What is more, it was completely absent
in control animal samples. We have no explanation for this striking result. Regarding the C group,
Anaerococcus and Streptococcus genera were found more prominent. A previous report confirmed a lower
relative abundance of the former genera in diabetic compared to healthy adults [65], contrary to our
results. The latter genera, however, presented a greater relative abundance in prediabetic [56], type 2
diabetic [66], and type 1 diabetic individuals [67] compared to their healthy controls, what matches
to our findings.
Among the 30 bacteria species statistically different between groups, eight Barnesiella spp.
were identified and five of them were greater in the treated group. A previous experimental
study reported an increased abundance of this genus in obese mice supplemented with prebiotics
which experienced a better glucose tolerance and important metabolic improvements [68]. We also
discovered that two Blautia spp. (B. coccoides and B. glucerasea) were more prominent in the control
animals. This genus belongs to the family Lachnospiraceae and includes butyrate producing bacteria
(BPB), a group which has been attributed many beneficial effects [69]. It was reported some positive
correlations between Blautia spp. and microbial products such as long-chain triglycerides [70] and
short chain fatty acids (SCFAs) [71], and parameters like BFG, insulin level, HOMA-IR, and weight
loss [56,72]. A decreased abundance of Blautia coccoides/Eubacterium rectale was found in T1D children
and was linked to intestinal disintegrity [73], while a randomized crossover study in healthy adults
reported a reduced abundance of Blautia genus after prebiotic supplementation [74]. These results
appear inconclusive. Our data also showed three Alistipes spp. enriched in the group supplemented
with the fermented product. On the contrary, previous works reported its enrichment in T1D [67] and
T2D individuals [12]. In the same way, our data revealed a lower abundance of two Streptococcus spp.
(S. thoraltensis and S. vestibularis) in the group which exhibited a better glucose control (T group) and
refute previous research [66].
The relative abundance of Anaerococcus, genus which includes many bacteria species which
produce butyrate in experimental conditions [75], was significantly enriched in the treated group.
Metagenome-wide association studies (MGWAS) on T2D humans revealed a compromised gut health
with an abnormal abundance of BPB, thus an enrichment of the aforementioned bacteria group could,
hypothetically, have led to improvements in the health status of the T group [12,46]. Regrettably,
this study did not confirm previous research and the treatment with the FFP did not induce changes
in well described BPB spp such as Akkermasia muciniphila. A. muciniphila is a mucus producer belonging
to the Verrucomicrobiae family which has been hypothesized to protect against T2D and obesity in animal
studies [69,76]. Increased levels of A. muciniphila were correlated to improvements in health parameters
in healthy [77,78] and HD-fed mice [76], and previous works in healthy mice showed that dietary
manipulation such as supplementation with prebiotics could increase the abundance of intestinal
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A. muciniphila [79]. It seems that the nutritional properties of the FFP and/or the study design did not
allow for a greater presence of A. muciniphila in the GM.
Regardless microbial populations, microbial metabolites are also of great importance and could be
partly responsible for the improved glucose control and gut health found in the T group. Considerable
interest exists in SCFAs such as acetate, propionate, and butyrate. They are lipid molecules known
to mediate in inflammation [80], gut permeability [81], energy expenditure and metabolism [51,82],
and an insulin-sensitizing [83] and antidiabetic effects [84,85] have also been described for them.
Taking it into consideration, the promotion of their physiological levels can lead to an improved overall
health, and may partly explain the favorable phenotype reported in the treated animals.
Since the FFP is rich in factors associated to a reduced food ingestion, such as fiber, microbial metabolites,
and probiotic LABs [86–88], a decreased food intake was expected in the treated group. However,
no considerable differences in eating behavior were observed between groups. This unexpected result
is in good agreement with other previous studies with fermented dairy product in STZ-induced
diabetic rats [25]. Similarly, BW was not significantly changed during the supplementation and was
indeed more prominent on the T group. Even though these results differ from an earlier in vivo
study [89] and a crossover trial in prediabetic humans [18] that found a protection from weight gain
for fermented products, they are consistent with previous finding in ZDF rats and other animal models
of T2D [90,91]. Although no anti-obesity effect was observed for the FFP, it remains unknown whether
it has some effect on body gain. May studies on another obesity rodent’s model elucidate the impact
of FFP on body mass regulation such as the ob/ob mouse model. The unexpected dramatic reduction
in BW in the C group could be consequence of an acute failure of the pancreatic function. The decline
in C-peptide levels in control rats suggest a low serum insulin level which, along with a compromised
insulin signaling would promote lipolysis and favor fat mobilization from the tissue [92,93]. In much
the same way, a FFP-mediated increase of SCFA levels in the T group, microbial metabolites known
to downregulate lipolysis [94–96], could have prevented from the loss of weight in the treated ZDF
rats. A previous report on Monascus fermented rice concluded that the differences in weight loss
between control versus treated animals could be caused by a depletion in the lean mass in the former as
results of diabetic complications [90]. In the present research, however, the nuclear magnetic resonance
revealed the absence of discrepancies in body composition after FFP supplementation. It differs from
previous results on fermented food in controlled intervention studies [18,97] and animals models [98]
which evidenced a significant decrease in body weight and fat depots. Nevertheless, the absence
of significant changes in body composition did not abstain from improvements in glucose homeostasis,
what matches well with previous findings in murine models of obesity [99,100].
With reference to the microbial diversity, the results of the analysis strongly indicate that the FFP
supplementation led to a greater diversity in the microbial communities which inhabit the gut
environment of the ZDF rats. Another plausible explanation may be that the FFP abstained from
the loss of diversity which consorts some clinical disorders such as obesity [48], however some
controversy does exist with regards to T2D [12]. It is well-known that dietary factors, along with
other external agents, have a great importance for the diversity and composition of the GM [101–103].
Previous works already studied changes in alpha-diversity with the consumption of diverse functional
compounds. For instance, a meta-analysis compared different prebiotic treatments, and their efficacy
in increasing bacteria richness was found to be dependent on the fiber used and the diversity index
calculated. The authors concluded that fiber interventions did not increase alpha-diversity [104].
They however suspected that a longer exposition would reveal some differences, what is in good
agreement with our findings. Further, other authors reached the conclusion that the bigger the diversity
of the GM, the bigger its resilience against external challenges [13]. This might consequently provide
a healthier phenotype since a low bacteria richness was found to be present in illnesses and pathological
conditions [103,105] and may this stability explain the better status reported for the treated group
in our study. However, a compromised gut richness is not always present on T2D according to findings
from a MGWAS with diabetic individuals [12] and bacterial diversity should not be the only focal
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point. Some authors call for a deeper approach and suggest that GM metabolic functionality, and not
only its phylogenetic composition, could be an interesting target for future research and shed light on
this point [106]. Then a more comprehensive approach is recommended.
This is not the first study reporting a hypoglycemic effect of probiotic bacteria or fermented
products in animal models, however, there is a critical need for well-designed, controlled studies
in humans to provide solid evidence of the suitability of fermented food for T2D management or
prevention. Although the evidence from controlled trials in humans is limited and arises from small
sample sizes [18,107], the number of work assessing the antidiabetic effects of fermented products
in humans continues to grow [98,108]. Different fermented food products were investigated for their
ability to exert antidiabetic effects and a wide variety of outcomes and levels of scientific evidence
were reported [27]. On account of the fact that the study sample was small, and it was a preliminary
attempt to test the FFP on an in vivo model, we strongly believe that a bigger sample size would have
evidence more differences in the analyzed parameters. Nevertheless, previous supplementation with
live bacteria in a different T2D murine model also failed to find significant differences in some metabolic
markers and it did not abstain from relevant beneficial effects in pancreatic function and glucose
homeostasis [109]. Nonetheless, the present research presents a valuable characteristic regarding
its experimental design. In contrast to some reports in the literature in which the supplementation
lasted for a few weeks [18,90,97], we supplemented the rats for a longer time period (31 weeks).
This prolonged exposition allowed us the examination of long-term responses.
Notwithstanding, as discussed above, we strongly believe that more work is needed to further
understand how FFP works and thereafter, validate its potential effectiveness in diabetic patients.
A future double-blind, placebo-controlled study with T2D individuals is being considered and would
provide insight into the potential antidiabetic properties of FFP in humans. As not all the strains
belonging to the same specie shares exactly the same beneficial effect [28,29], probably because of tiny
differences in their physical and chemical properties [110], a full and comprehensive identification
of the multi-species consortia of microorganisms presents in FFP, preferably up to strain level [111],
would be of great important for it further characterization.
5. Conclusions
In summary, we demonstrated that the FFP was favorable on glucose metabolism and contributed
to health maintenance, abstained from T2D harmful effects and improved overall life expectancy.
Our study is in line with previous studies showing that modulation of GM can confer health benefits on
T2D and OB. However, it is a fundamental issue to determine which component(s) present in the FFP
is/are responsible for the observed beneficial effects. Research into solving this dilemma is already
underway and we hope we could elucidate this issue. Future works on the topic would clearly be
worth pursuing. Importantly, the undeniable disparities between experimental models and humans
challenge the extrapolation of data from in vivo studies to humans, and a large well-controlled trial
with an appropriate study design and statistical methods is needed to provide firm evidence of FFP’s
antidiabetic properties.
These findings spotlight once again the role of microorganisms and gut function on the diabetic
pathology and indicate that novel fermented products could be a powerful tool to protect against
metabolic alterations. Nevertheless, very few publications are available in the literature that address
the application of fermented products in diabetic humans and discordance within conclusions makes
difficult the elucidation of reliable markers. Our results open the possibility to explore the effectivity
of innovative fermented food products in T2D, OB, and other non-communicable diseases in a
near future.
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